Latest pharma news

Jan 11, 2022

Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with...

Aug 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technol...

Aug 24, 2021

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Aug 10, 2021

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as...

Aug 05, 2021

Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acq...

Jul 15, 2021

Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety bar Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for the liver disease treatment arising from non-alcoholic steatohepatitis (NASH), declaring positive topline results from...

Jul 01, 2021

LivaNova Secures FDA Approval for Clinical Study to Assess the aura6000 System for Obstructive Sleep Apnea Treatment   On June 15, 2021, LivaNova PLC received approval from the US Food and Drug Administration (FDA) to continue with its investigational device exemption (IDE) clinical study, “Treating Ob...

Jun 10, 2021

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Jun 03, 2021

Abbott receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System for Aortic Stenosis treatment  On May 17, 2021, Abbott received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™. This marks the minimal...

May 13, 2021

Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus. Eli Lilly declared a drug development ...